GlobeNewswire Inc.··NaLexicon Advances Pain Drug After Positive Phase 2b Results
Lexicon Pharmaceuticals' pilavapadin shows promise in diabetic neuropathic pain study, supporting 10mg dose selection for Phase 3 trials.
LXRXclinical trialPhase 3
L
$LXRX
1 article found1 positive
0 negative
0 neutral